Scientific Program

8th Asian Biologics and Biosimilars Congress

August 10-12, 2017   Beijing, China
Day 1   August 10, 2017

Board Room

Keynote Forum

09:40-09:45  Introduction
Title: FDA/EMA current thinking on totality of evidence for development of biosimilars
Kamali Chance, Quintiles, IMS, USA

Group Photo

10:55-11:45  Title: Strategic partnership for China biologics
Jianguo Yang, Abpro, USA
Title: Biosimilars: Accelerating early clinical development
Raymond Huml, Quintiles IMS, USA

Networking & Refreshment Break: 10:35-10:55 @ Foyer area

Sessions:
Challenges in Developing Biosimilars | Cost Analysis of Biosimilars | Emerging Trends in Biosimilars | Emerging Biosimilars in Therapeutics

Session Chair: Darius Panaligan, Merck Group, Switzerland
Session Co-Chair: Hossein Pakdaman, Iranian Neurological Association, Iran

13:35-14:05  Title: Challenges in assessing therapeutic equivalence of nano-similars
Beat Fluehmann, Vifor Pharma Ltd, Switzerland

14:05-14:35  Title: Challenges and opportunities in biosimilar commercialization
Darius Panaligan, Merck Biosimilars, Switzerland

14:35-15:05  Title: Convergence of regulatory expectations
Robert Salcedo, Biosimilars Solutions and BioSciencesCorp, USA

Networking & Refreshment Break: 15:05-15:25 @ Foyer area

15:25-15:55  Title: From neuromodulation to drug discovery and treatment
Luis Ulloa, Rutgers University- New Jersey Medical School, USA

15:55-16:25  Title: The role of regulatory policies in relation to the local biosimilars production
Gustavo H Marin, UNLP-CONICET, Argentina

Day 1 Ends

Day 2   August 11, 2017

Board Room

Keynote Forum

10:00-10:05  Introduction
Title: Strategy for the global development of biosimilars: Putting it’s all together
Oxana Iliach, Quintiles IMS, Canada

Networking & Refreshment Break: 10:55-11:15 @ Foyer area

11:15-12:05  Title: Clinical development of biosimilars for Western markets: Planning for success
Charu Manaktala, Quintiles IMS, India

Sessions:
Globalization of Biosimilars | Biosimilars Market Challenges & Prospects | Pharmacovigilance of Biosimilars

Session Chair: Robert Salcedo, Biosimilars Solutions and BioSciencesCorp, USA
Session Co-Chair: Hossein Pakdaman, Iranian Neurological Association, Iran

13:05-13:35  Title: 10 year perspective: Science and commercial power- Battle of the giants in biosimilars
Richard Littlewood, Appliedstrategic, London, UK

Lunch Break: 12:05-13:05 @ Royal Cafe
13:35-14:05
Title: Biosimilars in the UK’s NHS: Attitudes, appetites and acceptance
Divya Chadha Manek, NHR, UK

14:05-14:35
Title: Comparison of biosimilar registration guidelines between EU and USA
Frank Cheng, Alban Pharma (Hong Kong) Co. Ltd., China

Special Session
14:35-15:15
Title: Biosimilars: Challenges in safety and risk management
Asif Mahmood, Pfizer, USA

Networking & Refreshment Break: 15:15-15:35 @ Foyer area

Poster Presentation @ 15:35-16:00

BS-01
Title: Theodor Bilharz Research Institute therapeutic products and health tools
Ismaeil Saad, Theodor Bilharz Research Institute, Egypt

BS-02
Title: Some considerations about biosimilar safety
Samer M Al-Hulu, Al-Qasim Green University, Iraq

BS-03
Title: Biosimilars: Overview, evolution and regulations assessment systematic development, regulations and molecules approved in Australia, Brazil, Malaysia, Japan, Singapore and South Korea
Tomas Gabriel BAS, Coquimbo, Chile

Day 2 Ends

Day 3   August 12, 2017

Board Room

Keynote Forum
10:00-10:05
Introduction

10:05-10:55
Title: Biosimilars in treatment of multiple sclerosis
Hossein Pakdaman, Iranian Neurological Association, Iran

Networking & Refreshment Break: 10:55-11:15 @ Foyer area

Sessions:
Emerging Biosimilars in Therapeutics | Clinical Studies on Biosimilars

11:15-11:45
Title: Practical considerations in clinical strategy to support the development of biologics device combination products
Zhaoyang Li, Sanofi, USA

11:45-12:15
Title: Patients as partners - transforming the delivery of clinical research in the NHS
Divya Chadha Manek, NHR, UK

12:15-12:45
Title: GMP Compliance: how critical to your success of biological product to the market
Frank Cheng, Alban Pharma (Hong Kong) Co. Ltd., China

12:45-13:15
Title: Expression of shiga-like toxin fused to vascular endothelial growth factor in E.coli for targeting angiogenesis
Osama O Ibrahim, Bioinnovation, USA

Lunch Break: 13:15-14:15 @ Royal Cafe

Networking and Closing Ceremony